Short interest for Calidi Biotherapeutics gives investors a sense of the degree to which investors are betting on the decline of Calidi Biotherapeutics's stock. Short interest data is updated every two weeks.

Calidi Biotherapeutics Stock (AMEX:CLDI), Short Interest Report

Calidi Biotherapeutics

Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.

Earnings

News

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Intraday Update

Markets

Trading Ideas

BNED

CLDI

JAGX

PACB

PALI

WISA

U.S. stocks traded mixed toward the end of trading, with the S&amp;P 500 falling around 0.3% on Tuesday.

The Dow traded up 0.02% to 37,741.96 while the NASDAQ fell 0.20% to 15,853.39. The S&amp;P 500 also fell, dropping, 0.28% to 5,047.76.

S&amp;P 500 Edges Lower; PacBio Shares Plunge

Movers

ACDC

ADXN

BACK

BENF

BSGM

CGEM

CSLR

CTNM

DFLI

DYNT

ERIC

ITCI

KAVL

MCBC

MNSO

PRFX

PRSO

PRZO

RNAC

RVYL

SKIL

SMXT

SPRC

SXTC

SYTA

TAOP

WFTC

Shares of  Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates.

Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 0.2% on Tuesday.

The Dow traded up 0.13% to 37,784.21 while the NASDAQ fell 0.20% to 15,853.34. The S&amp;P 500 also fell, dropping, 0.29% to 5,047.11.

Gold Moves Higher; Morgan Stanley Earnings Top Views

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics Inc

Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Precigen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>) with a Buy and maintains $6 price target.

Price Target

Reiteration

Analyst Ratings

PGEN

HC Wainwright & Co. Reiterates Buy on Precigen, Maintains $6 Price Target

<div>Year-End 2024 Exit Run-Rate Revenue of approximately&nbsp;$47 million&nbsp;to&nbsp;$53 million</div>
<ul>
<li>EveryLife is expected to reach and maintain cash flow positivity during 2024</li>
<li>Credova is expected to remain cash flow positive in 2024</li>
<li>PublicSquare intends to prioritize the development and growth of PSQPayments</li>
</ul>
&nbsp;
<ul>
<li>Expect to exit 2024 with approximately&nbsp;$8.0 million&nbsp;to&nbsp;$10.0 million&nbsp;of cash on the balance sheet</li>
</ul>

Guidance

PSQH

PublicSquare Says FY24 Revenue, Profitability, And Cash Position Outlook Remain Unchanged

TD Cowen analyst Andrew Charles maintains Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Hold and lowers the price target from $73 to $59.

JACK

TD Cowen Maintains Hold on Jack In The Box, Lowers Price Target to $59

Zomedica Announced The Launch Of Over-The-Air (OTA) Software And Firmware Update Capabilities For Its TRUFORMA Point-of-care Diagnostic Platform

<table cellspacing="0">
<tbody>
<tr>
<td colspan="1" rowspan="1">
First Quarter
Fiscal 2025
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
Full Year
Fiscal 2025&#x2A;
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
ARR
</td>
<td colspan="1" rowspan="1">
-
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$1,720&nbsp;-&nbsp;$1,735
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
As reported
</td>
<td colspan="1" rowspan="1">
-
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
14%&nbsp;-&nbsp;15%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Constant currency
</td>
<td colspan="1" rowspan="1">
-
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
15%&nbsp;-&nbsp;16%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Total revenue
</td>
<td colspan="1" rowspan="1">
$391&nbsp;-&nbsp;$393
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$1,644&nbsp;-&nbsp;$1,658
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
As reported
</td>
<td colspan="1" rowspan="1">
17%&nbsp;-&nbsp;18%
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
15%&nbsp;-&nbsp;16%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Constant currency
</td>
<td colspan="1" rowspan="1">
18%&nbsp;-&nbsp;19%
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
16%&nbsp;-&nbsp;17%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Subscription revenue
</td>
<td colspan="1" rowspan="1">
$374&nbsp;-&nbsp;$376
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$1,571&nbsp;-&nbsp;$1,585
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
As reported
</td>
<td colspan="1" rowspan="1">
18%&nbsp;-&nbsp;19%
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
16%&nbsp;-&nbsp;17%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Constant currency
</td>
<td colspan="1" rowspan="1">
19%
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
16%&nbsp;-&nbsp;17%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAP income from operations
</td>
<td colspan="1" rowspan="1">
$105&nbsp;-&nbsp;$108
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$459&nbsp;-&nbsp;$467
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAP operating margin
</td>
<td colspan="1" rowspan="1">
27%&nbsp;-&nbsp;27.5%
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
28%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAP net income
</td>
<td colspan="1" rowspan="1">
$86&nbsp;-&nbsp;$89
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$383&nbsp;-&nbsp;$392
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAP net income per diluted share
</td>
<td colspan="1" rowspan="1">
$0.29&nbsp;-&nbsp;$0.30
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$1.26&nbsp;-&nbsp;$1.29
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Diluted weighted average shares outstanding
</td>
<td colspan="1" rowspan="1">
301 - 302
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
303 - 305
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Free cash flow
</td>
<td colspan="1" rowspan="1">
-
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$386&nbsp;-&nbsp;$398
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Free cash flow margin
</td>
<td colspan="1" rowspan="1">
-
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
23.5%&nbsp;-&nbsp;24%
</td>
</tr>
</tbody>
</table>

Dynatrace Expects Q1 Revenue $391M-$393M Vs $393.58M Est, Adj EPS of $0.29-$0.30 Vs $0.30 Est

HC Wainwright &amp; Co. analyst Scott Buck reiterates Draganfly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) with a Buy and maintains $1 price target.

DPRO

HC Wainwright & Co. Reiterates Buy on Draganfly, Maintains $1 Price Target

Hut 8 Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) reported quarterly sales of $51.741 million which missed the analyst consensus estimate of $65.066 million by 20.48 percent. This is a 230.68 percent increase over sales of $15.647 million the same period last year.

Hut 8 Mining Q1 Sales $51.741M Miss $65.066M Estimate, Net Income $250.9M Up From $17.3M YoY

Biotech

Health Care

General

OCGN

Ocugen Completed Dosing In The Second Cohort Of Its Phase 1/2 GARDian Clinical Trial For OCU410ST (AAV-HRORA), A Modifier Gene Therapy Candidate For Stargardt Disease As A One-time Treatment

DRIO

DarioHealth Q1 Net Loss $(7.2)M Compared To $(12.8)M YoY

PSQ Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSQH#NYSE">PSQH</a>) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.39) by 12.82 percent. This is a 10 percent decrease over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $3.466 million which beat the analyst consensus estimate of $3.393 million by 2.15 percent. This is a 816.85 percent increase over sales of $378.034 thousand the same period last year.

Earnings Beats

Earnings Misses

PSQ Holdings Q1 2024 GAAP EPS $(0.44) Misses $(0.39) Estimate, Sales $3.466M Beat $3.393M Estimate

DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) reported quarterly sales of $5.758 million which missed the analyst consensus estimate of $6.758 million by 14.80 percent. This is a 18.51 percent decrease over sales of $7.066 million the same period last year.

DarioHealth Q1 Sales $5.758M Miss $6.758M Estimate

Dynatrace also announced today that its Board of Directors has authorized a share repurchase program for up to&nbsp;$500 million&nbsp;of common stock.

Buybacks

Dynatrace Board Approved a Share Buyback Program of up to $500M

Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.27 by 11.11 percent. The company reported quarterly sales of $380.848 million which beat the analyst consensus estimate of $375.285 million by 1.48 percent. This is a 21.11 percent increase over sales of $314.475 million the same period last year.

Dynatrace Q4 2024 Adj EPS $0.30 Beats $0.27 Estimate, Sales $380.848M Beat $375.285M Estimate

REE Automotive Ltd&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REE#NASDAQ">REE</a>) announced Wednesday that &nbsp;Penske Truck Leasing&nbsp;will begin offering Powered by REE EVs to its customers interested in electrifying their fleets for demos and orders, adding further momentum to REE&#8217;s current $50 million order book value.&nbsp;
REE Auto said Penske&#8217;s customers will have the opportunity to experience the intended benefits of the world&#8217;s first U.S. Federal Motor Vehicle Safety Standards (FMVSS) certified, software-driven, electric vehicle powered by REEcorner full by-wire technology, including:&nbsp;
<ul>
<li>Superior maneuverability and all-wheel drive functionality</li>
<li>Enhanced safety with fail-operational design via redundancies in hardware and software</li>
<li>Driver-centric cabin with excellent ergonomics and low chassis height</li>
<li>REEcorners designed for serviceability for a low total cost of ownership (TCO)</li>
<li>Strong residual values</li>
<li>Future-proofed, autonomous-ready and over-the-air (OTA) upgrade capable</li>
<li>Modular design and quick time to market</li>
<li>Optimal energy efficiency</li>
</ul>
Daniel Barel, CEO and co-founder of REE Automotive, said, &#8220;We are currently working on additional P7-C configurations to maximize utilization within Penske&#8217;s large product offering,&#8221;
REE collaborated with&nbsp;Wabash National Corp&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNC#NYSE">WNC</a>) to&nbsp;upfit&nbsp;the P7-C with a custom DuraPlate truck body utilizing the unique low floor, all-wheel steer, all-wheel drive full-by-wire P7-C characteristics.&nbsp;
Wabash&#8217;s DuraPlate technology&#8217;s lightweight properties enhance the feasibility of electric chassis for fleets while maintaining durability.&nbsp;
Vehicles Powered by REE are&nbsp;upfit-ready and designed to offer considerable benefits for body installations, including:
<ul>
<li>No Drill: Integrated mounting weld nuts so that bodies can be secured directly to frame rails</li>
<li>Battery Maintenance: Accessible from under the chassis</li>
<li>Flat Floor with integrated ramp: Structural advantages and weight savings by reducing the need for additional body mounting kits, and independent suspension to reduce body stresses. The ramp takes advantage of the low-floor box configuration.</li>
<li>Electrical Integration: Plug-and-play chassis harnesses for aftermarket electrical and ADAS systems</li>
<li>Driver Assistance Systems: Seamless integration of third-party systems; camera images can be viewed directly on the infotainment screen.</li>
</ul>
Price Action: REE shares closed higher by 4.26% at $4.65 on Tuesday.
Photo via Company

Market-Moving Exclusives

Exclusives

EXCLUSIVE: REE Partners with Penske to Launch P7-C EV Trucks, Enhancing Fleet Electrification Options

EWCZ

European Wax Center Reiterates FY24 Outlook For Total Revenue Of $225M-$232M (Est $230.391M), Same-Store Sales Growth Of 2%-5%

EXCLUSIVE: Ree Automotive Tells Benzinga Penske Truck Leasing To Offer Ree Automotive's P7-C EV Trucks To Its Customers For Demos And Orders Across North America

Wolfe Research analyst Steve Fleishman downgrades SunPower (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) from Peer Perform to Underperform.

Downgrades

SPWR

Wolfe Research Downgrades SunPower to Underperform

Guggenheim analyst Michael Schmidt downgrades Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) from Buy to Neutral.

BOLT

Guggenheim Downgrades Bolt Biotherapeutics to Neutral

European Wax Center Plans $50M Share Repurchase Program

New York Community Bancorp, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYCB#NYSE">NYCB</a>) shares are trading higher after it agreed to sell around&nbsp;$5 billion&nbsp;in mortgage warehouse loans to JPMorgan Chase Bank, N.A.&nbsp;of&nbsp;JPMorgan Chase &amp; Co.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>).
After the deal closes, the&nbsp;company&nbsp;projects that the transaction will add 65 basis points to the CET1 capital ratio, resulting in a pro-forma CET1 capital ratio&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/n38832538/new-york-community-bancorp-inc-agrees-to-sell-approximately-5-billion-in-warehouse-loans-to-jpmorg" rel="noreferrer noopener">of 10.8% as of&nbsp;March-end.</a>
The New York Community expects to reinvest sale proceeds into cash and securities.&nbsp;On a&nbsp;pro-forma&nbsp;basis, the ratio of cash and securities to total assets&nbsp;is projected&nbsp;to improve to 24% from 20% as of&nbsp;March-end.&nbsp;&nbsp;
Also, the&nbsp;bank&#8217;s pro-forma loan-to-deposit ratio&nbsp;is anticipated&nbsp;to decline to 104% compared to 110% at the end of the first quarter&nbsp;2024.
President and Chief Executive Officer Joseph Otting&nbsp;said, &#8220;Consistent with my guidance during our recent earnings call, we are moving forward quickly to implement our strategic plan, which focuses on improving our capital, liquidity, and loan-to-deposit metrics.&#8221;
&#8220;The mortgage team at Flagstar built a first-class warehouse business, which is reflected in our ability to execute&nbsp;on&nbsp;an accretive transaction with JP Morgan. The mortgage business remains an important business for the&nbsp;Company&nbsp;and we will continue to provide our mortgage customers and partners the same great service that they have come to expect from Flagstar.&#8221;
The sale&nbsp;is expected&nbsp;to close in the third quarter of 2024, subject to the completion of due diligence, negotiation of definitive documentation, and satisfaction of customary closing conditions.
As of&nbsp;March-end, New York Community&nbsp;had&nbsp;$112.9 billion&nbsp;of assets,&nbsp;$83.3 billion&nbsp;of loans,&nbsp;deposits of&nbsp;$74.9 billion, and total&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/n38545387/new-york-community-bancorp-inc-reports-first-quarter-2024-results-and-provides-update-on-its-strat" rel="noreferrer noopener">stockholders&#8217; equity of&nbsp;$8.4 billion</a>.
Investors can gain exposure to the stock via&nbsp;SPDR S&amp;P Regional Banking ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRE#NYSE">KRE</a>) and&nbsp;Royce Quant Small-Cap Quality Value ETF&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SQLV#NASDAQ">SQLV</a>).
Price Action: NYCB shares are up 5.91% at $4.12 premarket at the last check Wednesday.
Photo via Wikimedia Commons

Equities

Mid Cap

Asset Sales

NYCB

SQLV

Why Is New York Community Bancorp Stock Higher Premarket Wednesday?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Calidi Biotherapeutics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/cldi-stock-quote/">CLDI</a>) just reported results for the fourth quarter of 2023.<ul><li>Calidi Biotherapeutics reported earnings per share of -23 cents. This was below the analyst estimate for EPS of -20 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/cldi-stock-earnings-calidi-biotherapeutics-for-q4-of-2023/">CLDI Stock Earnings: Calidi Biotherapeutics Misses EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CLDI Stock Earnings: Calidi Biotherapeutics Misses EPS for Q4 2023

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Calidi Biotherapeutics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/cldi-stock-quote/">CLDI</a>) just reported results for the fourth quarter of 2023.<ul><li>Calidi Biotherapeutics reported earnings per share of -23 cents. This was below the analyst estimate for EPS of -20 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/cldi-stock-earnings-calidi-biotherapeutics-for-q4-of-2023/">CLDI Stock Earnings: Calidi Biotherapeutics Misses EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Calidi Biotherapeutics (CLDI – Research Report) today and set a price target of $2....

Optimistic Outlook for Calidi Biotherapeutics Despite Financial Hurdles: A Buy Rating Justified by Promising Oncology Pipeline

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth diving into on Tuesday as we check out all of the biggest changes and the news behind them!



Moving stocks this morning are earnings reports, an acquisition agreement, proposed public offerings and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Dynatronics (NASDAQ:<a href="https://investorplace.com/stock-quotes/dynt-stock-quote/">DYNT</a>) stock is rocketing more than 97% alongside heavy pre-market trading.</li>



<li>Dragonfly Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/dfli-stock-quote/">DFLI</a>) shares are soaring close to 55% after releasing its <a href="https://www.nasdaq.com/press-release/dragonfly-energy-reports-fourth-quarter-2023-and-full-year-financial-results-2024-04">Q4 2023 earnings report</a>.</li>



<li>Macatawa Bank (NASDAQ:<a href="https://investorplace.com/stock-quotes/mcbc-stock-quote/">MCBC</a>) stock is surging over 38% after <a href="https://www.globenewswire.com/news-release/2024/04/15/2863147/11955/en/Wintrust-Financial-Corporation-and-Macatawa-Bank-Corporation-Announce-Plans-to-Merge.html">signing an acquisition agreement</a>.</li>



<li>WiSA Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/wisa-stock-quote/">WISA</a>) shares are rising more than 26% <a href="https://www.nasdaq.com/press-release/wisa-technologies-announces-reverse-stock-split-2024-04-10">following a reverse stock split</a>.</li>



<li>Mobilicom (NASDAQ:<a href="https://investorplace.com/stock-quotes/mob-stock-quote/">MOB</a>) stock is gaining over 21% on plans to show off an <a href="https://www.nasdaq.com/press-release/mobilicom-to-unveil-unprecedented-comprehensive-solution-for-uncrewed-vehicle-systems">uncrewed vehicle system</a>.</li>



<li>HNR Acquisition (NYSEMKT:<a href="https://investorplace.com/stock-quotes/hnra-stock-quote/">HNRA</a>) shares are increasing more than 18% without any clear news this morning.</li>



<li>Shuttle Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/shph-stock-quote/">SHPH</a>) stock is climbing over 18% despite a lack of news.</li>



<li>Taoping (NASDAQ:<a href="https://investorplace.com/stock-quotes/taop-stock-quote/">TAOP</a>) shares are getting a more than 16% boost without any obvious news to report.</li>



<li>Global Gas (NASDAQ:<a href="https://investorplace.com/stock-quotes/hgas-stock-quote/">HGAS</a>) stock is jumping over 16% on Tuesday morning.</li>



<li>Kaixin (NASDAQ:<a href="https://investorplace.com/stock-quotes/kxin-stock-quote/">KXIN</a>) shares are up more than 14% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Ryvyl (NASDAQ:<a href="https://investorplace.com/stock-quotes/rvyl-stock-quote/">RVYL</a>) stock is diving over 29% on a <a href="https://www.nasdaq.com/press-release/ryvyl-inc.-announces-launch-of-proposed-underwritten-public-offering-2024-04-15">proposed public offering</a>.</li>



<li>Calidi Biotherapeutics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/cldi-stock-quote/">CLDI</a>) shares are tumbling more than 22% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318234211&amp;type=PDF&amp;symbol=CLDI&amp;cdn=ab45db11645ce0b64dd38dde47e4a59d&amp;companyName=Calidi+Biotherapeutics+Inc.&amp;formType=S-1%2FA&amp;formDescription=%5BAmend%5D+General+form+for+registration+of+securities+under+the+Securities+Act+of+1933&amp;dateFiled=2024-04-15">proposed public offering</a>.</li>



<li>Inovio Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/ino-stock-quote/">INO</a>) stock is taking an over 22% beating after <a href="https://finance.yahoo.com/news/inovio-announces-pricing-approximately-36-223900148.html">pricing an underwritten offering</a>.</li>



<li>MDJM (NASDAQ:<a href="https://investorplace.com/stock-quotes/mdjh-stock-quote/">MDJH</a>) shares are sliding more than 15% on Tuesday morning.</li>



<li>Addex Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/adxn-stock-quote/">ADXN</a>) stock is dropping over 12% this morning.</li>



<li>Qilian (NASDAQ:<a href="https://investorplace.com/stock-quotes/qli-stock-quote/">QLI</a>) shares are decreasing more than 10% today.</li>



<li>Indonesia Energy (NYSEMKT:<a href="https://investorplace.com/stock-quotes/indo-stock-quote/">INDO</a>) stock is falling over 10% this morning.</li>



<li>US Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/useg-stock-quote/">USEG</a>) shares are slipping more than 10% on Tuesday.</li>



<li>Poseida Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/pstx-stock-quote/">PSTX</a>) stock is dipping over 9% today.</li>



<li>OMNIQ (NASDAQ:<a href="https://investorplace.com/stock-quotes/omqs-stock-quote/">OMQS</a>) shares close out our pre-market stock movers down more than 9%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-april-16th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Calidi Biotherapeutics slumps 54%, prices $6.1M equity

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Calidi Biotherapeutics&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/cldi-stock-quote/">CLDI</a>) stock is falling on Tuesday after the clinical stage immuno-oncology company <a href="https://finance.yahoo.com/news/calidi-biotherapeutics-inc-announces-pricing-123100345.html">priced a public offering</a> of its shares.



The company is selling 15,197,500 shares of CLDI stock for 40 cents per share. Each of these shares also comes with several warrants to acquire additional shares of Calidi Biotherapeutics.



The warrants included in this offering include Series A Common Warrants and Series B Unit Warrants. Each of these includes one share of CLDI stock and a Series B-1 Common Warrant and Series C Unit Warrant. The Series B-1 Common Warrant and Series C Unit Warrant are exercisable for one share of common stock and a Series C-1 Common Warrant.



All of the common warrants in this offering are exercisable for 60 cents. Series A Common Warrants, Series B Unit Warrants and Series C Unit Warrants are exercisable immediately.



The Series A Common Warrant, the Series B-1 Warrant and the Series C-1 Common Warrant expire in five years, the Series B common warrants expire in 12 months and the Series C common warrants expire in four months.



<h2>CLDI Stock Offering Plans</h2>



Calidi Biotherapeutics notes that it expects gross proceeds of $6.1 million from this offering. The company intends to use this money for working capital and general corporate purposes, as well as for pre-clinical and clinical trials.



The reason all this has stock down today is the fear of dilution of stockholder&rsquo;s stakes in Calidi Biotherapeutics. Adding to that is the offering price of 40 cents being below its prior closing price.



CLDI stock is down 50.8% as of Tuesday morning.



There are more stock market stories available below!



We have all of the latest stock market news on Tuesday! That includes everything happening with shares of Ryvyl&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rvyl-stock-quote/">RVYL</a>) stock, Dragonfly Energy&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/dfli-stock-quote/">DFLI</a>) stock and Dynatronics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/dynt-stock-quote/">DYNT</a>) stock today. All of that news is available at the following links!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/04/why-is-ryvyl-rvyl-stock-down-10-today/">Why Is Ryvyl (RVYL) Stock Down 10% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-dragonfly-energy-dfli-stock-up-56-today/">Why Is Dragonfly Energy (DFLI) Stock Up 56% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-dynatronics-dynt-stock-up-93-today/">Why Is Dynatronics (DYNT) Stock Up 93% Today?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/why-is-calidi-biotherapeutics-cldi-stock-down-51-today/">Why Is Calidi Biotherapeutics (CLDI) Stock Down 51% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Calidi Biotherapeutics (CLDI) Stock Down 51% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
BuzzFeed (NASDAQ:<a href="https://investorplace.com/stock-quotes/bzfd-stock-quote/">BZFD</a>) stock is a hot topic on Tuesday as the media company is seeking approval for a reverse stock split at its next shareholder meeting.



That shareholder meeting is <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318231087&amp;type=PDF&amp;symbol=BZFD&amp;cdn=5a25da9db799f571a5965dcfcb4d5709&amp;companyName=BuzzFeed+Inc.&amp;formType=DEF+14A&amp;formDescription=Other+definitive+proxy+statements&amp;dateFiled=2024-04-11">set for April 25</a> and will have investors voting on several matters. Among them is a request to allow it to consolidate shares of its outstanding stock.



BuzzFeed is seeking approval for a reverse stock split ranging from a 1-for-2 to 1-for-25 basis. If investors approve this plan, the company will decide on the ratio of its reverse stock split later.



Following approval, BuzzFeed will also have to decide on a time for the reverse stock split. The filing covering its shareholder meeting says it would do so within one year of getting stockholder approval.



<h2>Why a Reverse Stock Split for BZFD Shares?</h2>



BuzzFeed has had it rough ever since the company went public via a special purpose acquisition company (SPAC) merger. That initially saw an incredible drop in value shortly after it went public in December 2021.



And that negative momentum hasn&rsquo;t stopped since then. As a result, shares of BZFD stock are only trading for about 39 cents each as of this writing. This puts the company in danger of being delisted as it&rsquo;s below the $1 minimum bid required for a Nasdaq listing.



BuzzFeed is obviously looking to use its reverse stock split to boost the price of BZFD shares. Investors will want to keep an eye on the company to see how that works out for it.



BZFD stock is down 4.8% as of Tuesday morning.



Investors can find more of the most recent stock market stories below!



We have all of the hottest stock market news ready to go on Tuesday! With that comes coverage of Trump Media &amp; Technology&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/djt-stock-quote/">DJT</a><a href="https://investorplace.com/cryptocurrency//"></a><a href="https://investorplace.com/stock-quotes/-stock-quote/"></a>), Calidi Biotherapeutics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/cldi-stock-quote/">CLDI</a>) and Kratos Defense&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ktos-stock-quote/">KTOS</a>) shares. All of this news is ready to go at the following links!



<h2>More Tuesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/04/djt-stock-21-million-reasons-trump-media-shares-are-struggling-to-stay-afloat/">DJT Stock: 21 Million Reasons Trump Media Shares Are Struggling to Stay Afloat</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-calidi-biotherapeutics-cldi-stock-down-51-today/">Why Is Calidi Biotherapeutics (CLDI) Stock Down 51% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/trade-of-the-day-wager-on-kratos-defense-ktos-stock-as-drone-demand-heats-up/">Trade of the Day: Wager on Kratos Defense (KTOS) Stock as Drone Demand Heats Up</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/bzfd-stock-buzzfeed-is-prepping-for-a-reverse-stock-split/">BZFD Stock: BuzzFeed Is Prepping for a Reverse Stock Split</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BZFD Stock: BuzzFeed Is Prepping for a Reverse Stock Split

Calidi Biotherapeutics (CLDI) has shared an announcement. Calidi Biotherapeutics, Inc. successfully raised approximately $6.1 million through a pub...

Calidi Biotherapeutics Bolsters Finance with Strategic Offering

Calidi Biotherapeutics (CLDI) just unveiled an announcement. Calidi Biotherapeutics, Inc. has released updated presentation slides detailing compan...

Calidi Biotherapeutics Shares Informative Investor Presentation Slides

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Calidi Biotherapeutics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/cldi-stock-quote/">CLDI</a>) just reported results for the first quarter of 2024.<ul><li>Calidi Biotherapeutics reported earnings per share of -20 cents. This was above the analyst estimate for EPS of -27 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/cldi-stock-earnings-calidi-biotherapeutics-for-q1-of-2024/">CLDI Stock Earnings: Calidi Biotherapeutics Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CLDI Stock Earnings: Calidi Biotherapeutics Beats EPS for Q1 2024

BZFD

HGAS

HNRA

INDO

KTOS

KXIN

MDJH

OMQS

PSTX

SHPH

USEG

Press Releases

Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results

Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company's Novel Immunotherapies at the AACR Annual Meeting 2024

Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering

Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24

Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Calidi Biotherapeutics Stock (AMEX:CLDI), Short Interest Report

People Also Watch